Lisata reports Phase 2 ASCEND Cohort A: mOS 12.68 vs 9.72 months; 4 complete responses

LISATA THERAPEUTICS, INC.

Cohort A: median OS of 12.68 months for certepetide plus chemo vs 9.72 months for placebo plus chemo.
Complete responses: 4 of 65 (6.2%) in certepetide group; 0 of 28 in placebo group.
Median PFS was 5.5 months in both arms; 6-month PFS trend favored certepetide.
Cohort B (two-dose regimen) data expected in coming months; full data from both cohorts to follow.
Lisata plans to advance certepetide to Phase 3 in early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.